Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial  by Burn, John et al.
Articles
www.thelancet.com   Vol 378   December 17/24/31, 2011 2081
Lancet 2011; 378: 2081–87
Published Online
October 28, 2011
DOI:10.1016/S0140-
6736(11)61049-0
See Comment page 2051
Institute of Genetic Medicine, 
Newcastle University, 
Newcastle upon Tyne, UK 
(Prof Sir J Burn MD, 
Prof A-M Gerdes MD, G Barker); 
Clinical Genetics, Rigshospital, 
Copenhagen, Denmark 
(Prof A-M Gerdes); Colorectal 
Medicine and Genetics, Royal 
Melbourne Hospital, 
Melbourne, VIC, Australia 
(Prof F Macrae MD); Department 
of Surgery, Jyväskylä Central 
Hospital, University of Eastern 
Finland, Jyväskylä, Finland 
(Prof J-P Mecklin MD, 
K Pylvanainen); 
St Josefs-Hospital, 
Bochum-Linden, Germany 
(G Moeslein MD); Département 
d’Oncologie Génétique, Institut 
Paoli Calmettes, Marseille, 
France (S Olschwang MD); 
Clinical Genetics Unit, Princess 
Anne Hospital, Southampton, 
UK (Prof D Eccles MD, 
G Crawford); Department of 
Medical Genetics, St Mary’s 
Hospital, Manchester, UK 
(Prof D G Evans MD); Medical and 
Molecular Genetics, University 
of Birmingham, Birmingham, 
UK (Prof E R Maher MD); Istituto 
Nazionale per lo Studio e, 
la Cura dei Tumori, Milan, Italy 
(L Bertario MD); Medical Genetics 
Clinic, ICMM, University of 
Copenhagen, Hvidovre, 
Denmark (M-L Bisgaard MD); 
MRC Human Genetics Unit, 
Western General Hospital, 
Edinburgh, UK 
(Prof M G Dunlop MD); 
Hereditary GI Cancer Registry, 
Department of Surgery, Queen 
Mary Hospital, Hong Kong, 
China (J W C Ho MD); St George’s 
Hospital, London, UK 
Long-term eﬀ ect of aspirin on cancer risk in carriers of 
hereditary colorectal cancer: an analysis from the CAPP2 
randomised controlled trial
John Burn, Anne-Marie Gerdes, Finlay Macrae, Jukka-Pekka Mecklin, Gabriela Moeslein, Sylviane Olschwang, Diane Eccles, D Gareth Evans, 
Eamonn R Maher, Lucio Bertario, Marie-Luise Bisgaard, Malcolm G Dunlop, Judy W C Ho, Shirley V Hodgson, Annika Lindblom, Jan Lubinski, 
Patrick J Morrison, Victoria Murday, Raj Ramesar, Lucy Side, Rodney J Scott, Huw J W Thomas, Hans F Vasen, Gail Barker, Gillian Crawford, 
Faye Elliott, Mohammad Movahedi, Kirsi Pylvanainen, Juul T Wijnen, Riccardo Fodde, Henry T Lynch, John C Mathers, D Timothy Bishop, 
on behalf of the CAPP2 Investigators
Summary
Background Observational studies report reduced colo rectal cancer in regular aspirin consumers. Randomised 
controlled trials have shown reduced risk of adenomas but none have employed prevention of colorectal cancer as a 
primary endpoint. The CAPP2 trial aimed to investigate the antineoplastic eﬀ ects of aspirin and a resistant starch in 
carriers of Lynch syndrome, the major form of hereditary colorectal cancer; we now report long-term follow-up of 
participants randomly assigned to aspirin or placebo.
Methods In the CAPP2 randomised trial, carriers of Lynch syndrome were randomly assigned in a two-by-two factorial 
design to 600 mg aspirin or aspirin placebo or 30 g resistant starch or starch placebo, for up to 4 years. Randomisation 
was in blocks of 16 with provision for optional single-agent randomisation and extended postintervention double-
blind follow-up; participants and investigators were masked to treatment allocation. The primary endpoint was 
development of colorectal cancer. Analysis was by intention to treat and per protocol. This trial is registered, 
ISRCTN59521990.
Results 861 participants were randomly assigned to aspirin or aspirin placebo. At a mean follow-up of 55·7 months, 
48 participants had developed 53 primary colorectal cancers (18 of 427 randomly assigned to aspirin, 30 of 434 to 
aspirin placebo). Intention-to-treat analysis of time to ﬁ rst colorectal cancer showed a hazard ratio (HR) of 0·63 (95% CI 
0·35–1·13, p=0·12). Poisson regression taking account of multiple primary events gave an incidence rate ratio (IRR) of 
0·56 (95% CI 0·32–0·99, p=0·05). For participants completing 2 years of intervention (258 aspirin, 250 aspirin 
placebo), per-protocol analysis yielded an HR of 0·41 (0·19–0·86, p=0·02) and an IRR of 0·37 (0·18–0·78, p=0·008). 
No data for adverse events were available postintervention; during the intervention, adverse events did not diﬀ er 
between aspirin and placebo groups.
Interpretation 600 mg aspirin per day for a mean of 25 months substantially reduced cancer incidence after 
55·7 months in carriers of hereditary colorectal cancer. Further studies are needed to establish the optimum dose and 
duration of aspirin treatment.
Funding European Union; Cancer Research UK; Bayer Corporation; National Starch and Chemical Co; UK Medical 
Research Council; Newcastle Hospitals trustees; Cancer Council of Victoria Australia; THRIPP South Africa; The 
Finnish Cancer Foundation; SIAK Switzerland; Bayer Pharma.
Introduction
People with monogenic predisposition to cancer oﬀ er an 
ideal focus for chemoprevention trials; the high probability 
of early tumours provides statistical power, and knowledge 
of genetic basis reduces heterogeneity while providing 
data relevant to patients whose sporadic cancers involve 
the same molecular pathway. Existing planned surveillance 
reduces cost and the relevance to family members 
encourages patient compliance. The Colorectal Adenoma/
carcinoma Prevention Programme (CAPP) was launched 
in 1990. CAPP1 investigated 200 young people with 
familial adenomatous polyposis. CAPP2, the ﬁ rst large-
scale genetically targeted chemo prevention trial, focused 
on 1000 people with Lynch syndrome (also known as 
hereditary non-polyposis colon cancer or HNPCC), most 
carrying pathological DNA mismatch repair (MMR) gene 
variants, plus previously aﬀ ected patients within families 
meeting the Amsterdam criteria.1
Both trials used a factorial two-by-two design to assess 
two agents, aspirin and resistant starch, thought to 
protect against colorectal cancer. CAPP1 revealed a weakly 
signiﬁ cant eﬀ ect of aspirin on size of largest observed 
polyp and a signiﬁ cant reduction in crypt length in 
participants given resistant starch.2 In CAPP2 over 
6 years, 937 people from 43 international centres 
commenced intervention.3 After intervention, mean 
29 months, there was no evidence that either agent 
aﬀ ected development of colonic neoplasia, with most 
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lesions being adenomas.3 In view of cohort and case-
control evidence of a protective eﬀ ect of aspirin against 
colorectal cancer only after long-term exposure,4 the 
original design of the CAPP2 study included double-
blind post-intervention follow-up for at least 10 years.
At the end of the intervention period,3 128 participants 
had developed at least one adenoma and 23 had developed 
colorectal cancer. These were pooled for analysis as 
neoplasia since the primary endpoint of colorectal cancer 
was judged unlikely to be aﬀ ected within 4 years in a 
population under colonoscopic surveillance. We now 
report the eﬀ ect of aspirin on the incidence of colorectal 
cancer, the primary CAPP2 outcome, and other Lynch 
syndrome cancers as secondary outcomes. The baseline 
population of 861 participants (randomly assigned to 
aspirin or aspirin placebo in the randomised controlled 
trial) diﬀ ers from our ﬁ rst report, which was conﬁ ned to 
those with an exit colonoscopy.
Methods
Trial design and participants
Between January, 1999, and March, 2005, 937 carriers of 
Lynch syndrome started intervention in the CAPP2 
study3,5 and 746 were included in the end-of-intervention 
analysis (mean 29 months). Randomisation was in blocks 
of 16 in a two-by-two factorial design to aspirin (600 mg), 
aspirin placebo, resistant starch (30 g; Novelose, National 
Starch and Chemical Co, NJ, USA), and resistant starch 
placebo. Of the 937 participants, 427 were randomly 
assigned to aspirin, 434 to aspirin placebo, and the 
remaining recruits were not randomly assigned for the 
aspirin intervention, having opted not to participate in 
this part of the study (n=76; almost all due to perceived 
aspirin sensitivity or history of peptic ulceration). All 
participants who refused randomisation to the aspirin 
groups were randomly assigned to the resistant starch or 
resistant starch placebo intervention only (ﬁ gure 1; 
webappendix p 1). Participants and investigators were 
masked to treatment allocation; one participant asked to 
be informed of her randomisation status after leaving the 
study. The study had a preplanned design for 10 years’ 
follow-up; at the time of this analysis, the earliest enrolled 
participants had reached the 10-year threshold. All 
participants consented to long-term follow-up at recruit-
ment and more detailed consent was obtained in the later 
stages of the study to ensure continued support.
The primary outcome of CAPP2 was development of 
colorectal cancer; the secondary outcomes were develop-
ment of colorectal adenomas or the development of other 
Lynch syndrome-related cancers, or both. This analysis 
focused on 861 CAPP2 participants randomly assigned to 
aspirin or aspirin placebo from entry until the latest date 
for which the recruiters had information about cancer 
diagnosis—a timepoint usually corresponding to the date 
of last surveillance attendance. Our analysis included 
Lynch syndrome cancers that were included in the earlier 
report,3 those that occurred subsequent to exit from the 
intervention phase, and all cancers that occurred in people 
without an exit colonoscopy, which excluded them from 
the statistical analysis in our earlier report.3 As a result of 
dispersed international recruitment and because routine 
surveillance was provided by local health-care teams, 
records of adenoma occurrence in CAPP2 participants 
subsequent to the intervention phase are incomplete. 
Similarly, no details of adverse events were available 
postintervention; during the intervention phase, adverse 
events in the aspirin and placebo groups were similar 
(webappendix p 2).3 There was also no signiﬁ cant diﬀ erence 
in compliance (ie, proportion of scheduled tablets not 
taken during the intervention phase) between the aspirin 
and aspirin placebo groups for participants with complete 
inter vention phase data (χ²(1)=1·27, p=0·20).3
Statistical analysis
This analysis was designed to test the primary hypothesis 
that aspirin would reduce the development of colorectal 
cancer (as primary outcome) and Lynch syndrome cancers 
(as secondary outcome) in 861 participants randomly 
assigned to aspirin (n=427) or aspirin placebo (n=434). 
The original protocol invited participants to continue 
with the original intervention for a further 2-year cycle 
after the initial 2 years. Two analytical approaches were 
taken: ﬁ rst, time to ﬁ rst occurrence of colorectal cancer 
(our original focus), which was examined with life-table 
methods and Cox proportional hazards; and second, 
Poisson regression modelling to investigate primary 
cancers at multiple anatomical sites, a feature of Lynch 
syndrome. Poisson regression analysis took into account 
the complete cancer history of the participant since 
randomisation, by contrast with the more restricted time-
to-ﬁ rst-event analysis.
For life-table analysis, end of follow-up was determined 
as the time of ﬁ rst diagnosis of colorectal cancer, if the 
participant was aﬀ ected, or the last recorded date at which 
clinical status was known. Analyses included Cox 
proportional hazards models to estimate sex-adjusted 
hazard ratios (HRs) and 95% CIs, and Kaplan-Meier 
curves to assess non-parametrically the outcome 
diﬀ erences between the aspirin and aspirin placebo 
interventions. The assumption of proportional hazard 
was tested to assess compliance. For the Poisson 
regression analysis, incidence rate ratios (IRRs) for the 
eﬀ ect of aspirin adjusted for sex were estimated from log-
linear models for the number of primary cancers 
diagnosed after randomisation; exposure time was from 
randomisation until date of last known clinical status.
All analyses used Stata (version 10). Analyses were 
undertaken on an intention-to-treat basis (ie, intervention 
assigned at randomisation) and per protocol (restricting 
consideration to those taking aspirin [or aspirin placebo] 
for at least 2 years). A secondary planned analysis ad-
dressed incidence of Lynch syndrome cancer, including 
new cancers thought to result from the underlying genetic 
defect. Designation of Lynch syndrome cancer spectrum 
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was a clinical assessment, masked to inter vention, and 
based on a review of the Lynch syndrome phenotype;6 
endometrial, ovarian, pancreatic, small bowel, gall 
bladder, ureter, stomach, and kidney cancers and cancer 
of the brain were included. A ﬁ nal analysis examined the 
total burden of Lynch syndrome-related cancers in 
participants who had been on intervention for at least 
2 years (per protocol). All p values reported are two-sided 
(in keeping with the original sample-size calculation).
This trial is registered, ISRCTN59521990.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Recruitment ran from Jan 1, 1999, to March 10, 2005. The 
mean observation period was 55·7 months (range 1–128) 
and eight (1%) recruits were 10 years or more from 
randomisation by the time of the present analysis 
(table 1). Times are measured from the date of 
randomisation. For 671 participants, we report both data 
for during the intervention and for longer follow-up, 
whereas for 190 we report on-intervention information 
only (webappendix p 3). Demographic data show no 
diﬀ erences between those traced and not traced in this 
follow-up analysis with respect to age, sex, randomisation 
category, or geographical location (data not shown), 
although the development of a cancer could make follow-
up reporting more complete. There were no signiﬁ cant 
regional diﬀ erences in incidence of colorectal cancer 
(data not shown; χ²(2)=5·03, p=0·08).
Table 1 summarises the cancer burden in the study 
population. Overall, 40 people with postintervention 
information were diagnosed with colorectal cancer 
(13 of 342 allocated aspirin and 27 of 329 allocated 
aspirin placebo). Colo rectal cancer occurred in a further 
eight people among 190 individuals with information 
about the intervention phase only (ﬁ ve of 85 patients on 
aspirin and three of 105 on aspirin placebo; ﬁ gure 1; 
web appendix p 4).
Evidence has emerged of delayed protection by aspirin 
against cancer. For the whole postrandomisation period, 
the HR for colorectal cancer was 0·63 (95% CI 0·35–1·13, 
p=0·12), favouring protection in the aspirin group 
(table 2; ﬁ gure 2). Five of 48 people who developed 
colorectal cancer each had two primary colon cancers. 
Of these, one had received aspirin and four aspirin 
placebo. Although the intention-to-treat time-to-event 
analysis showed a non-signiﬁ cant protective eﬀ ect of 
aspirin, the Poisson regression taking into account the 
ﬁ ve participants with multiple primary colorectal cancer 
(53 cancers) indicated a protective eﬀ ect (IRR 0·56, 
95% CI 0·32–0·99, p=0·05). We re-estimated this 
pro tective eﬀ ect with a per-protocol analysis and obtained 
similar results.
We examined outcomes in participants who took 
aspirin (or aspirin placebo) for a minimum of 2 years, 
deﬁ ned as consumption of 1400 (300 mg) tablets (rounded 
down from a 2-year total [1461 tablets] to allow for early 
scheduling of the exit colonoscopy or occasional missed 
dosage). On the basis of this deﬁ nition, 258 (60%) of 
those on aspirin and 250 (58%) of those on aspirin 
placebo were treated for 2 years or longer. The HR for 
1071 participants allocated randomisation number
62 judged ineligible
76 requested
randomisation to
RS or RSP only
434 allocated aspirin placebo
434 analysed
105 on-trial information
only (3 CRC diagnoses)
329 longer follow-up
(27 CRC diagnoses)
427 analysed
85 on-trial information
only (5 CRC diagnoses)
342 longer follow-up
(13 CRC diagnoses)
427 allocated aspirin (600 mg)
72 eligible, but
withdrew consent
before intervention
commenced
937 eligible commenced
intervention and
subject to analysis
Figure 1: Trial proﬁ le
RS=resistant starch. RSP=resistant starch placebo. CRC=colorectal cancer.
Aspirin 
(n=427)
Aspirin placebo 
(n=434)
Total 
(n=861)
Time in CAPP2 intervention study (months) 25·0 
(12·5; 0·8–60·6)
25·4 
(14·2; 1·1–74·4)
25·2 
(13·4; 0·8–74·4)
Time since study entry (months) 56·6 
(30·9; 0·8–125·4)
54·8 
(31·8; 1·6–128·0)
55·7 
(31·4; 0·8–128·0)
Participants with ﬁ rst colorectal cancer
Since randomisation 18 30 48
Within 2 years of randomisation 10 10 20
More than 2 years from randomisation 8 20 28
Participants with other Lynch syndrome cancers*
Since randomisation 16 24 40
Within 2 years of randomisation 5 9 14
More than 2 years from randomisation 11 15 26
Participants with one or more Lynch syndrome 
cancer (including colorectal)
Since randomisation 34 52 86
Within 2 years of randomisation 15 19 34
More than 2 years from randomisation 19 33 52
Participants with non-Lynch syndrome cancers 19 19 38
Data are mean (SD; range) or n. *Two participants in the placebo group each had a colorectal cancer and another Lynch 
syndrome cancer; these participants were counted in the rows relating to both colorectal and other Lynch syndrome 
cancers; in the row relating to all Lynch syndrome cancers, these participants were counted only once.
Table 1: Study population
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those taking aspirin for 2 years or longer was 0·41 
(95% CI 0·19–0·86, p=0·02; table 2, ﬁ gure 2) and the 
IRR was 0·37 (95% CI 0·18–0·78, p=0·008). These 
results are similar to those for Poisson regression in the 
intention-to-treat analysis.
We explored the eﬀ ect of compliance on outcome (which 
is important because non-compliance could be related to 
factors that also aﬀ ect risk of colorectal cancer) using per-
protocol analysis, and found that participants who took 
aspirin for 2 years or more had an incidence rate of 
0·06 per 100 person-years compared with 0·13 per 
100 person-years in those who took aspirin for less than 
2 years. A similar analysis within the placebo group 
showed no signiﬁ cant diﬀ erence in incidence of colo rectal 
cancer between participants who took aspirin placebo for 
2 years or more (0·14 per 100 person years) compared with 
those who took aspirin placebo for less than 2 years 
(0·10 per 100 person years; data not shown).
We also undertook a planned secondary analysis with 
other Lynch syndrome cancers as the outcome. 
18 participants developed endometrial cancer, of whom 
ﬁ ve were randomly assigned to aspirin and 13 to aspirin 
placebo; in total, 38 participants developed cancer at a 
site other than the colorectum (additionally, two 
participants had colorectal and another Lynch syndrome 
cancer) of whom 16 were randomly assigned to aspirin 
and 22 to aspirin placebo (webappendix p 5). The HR for 
those randomly assigned to aspirin was 0·63 (95% CI 
0·34–1·19 p=0·16, table 2; webappendix p 6) and the IRR 
was 0·63 (95% CI 0·34–1·16 p=0·14) compared with the 
aspirin placebo group. Per-protocol analysis showed an 
HR for those who had taken aspirin for 2 years or more 
of 0·47 (95% CI 0·21–1·06, p=0·07) with an IRR of 0·49 
(95% CI 0·23–1·05 p=0·07; table 2).
Table 2 shows the combined analysis of all Lynch 
syndrome cancers including colorectal cancer. On 
intention-to-treat analysis, the HR was 0·65 (95% CI 
0·42–1·00, p=0·05) and IRR was 0·59 (95% CI 0·39–0·90, 
p=0·01), and in the per-protocol analysis the HR was 
0·45 (0·26–0·79, p=0·005; ﬁ gure 3) and the IRR was 
0·42 (0·25–0·72, p=0·001), supporting the protective 
eﬀ ect of aspirin. Cox proportional hazards model analysis 
by cumulative aspirin consumption suggested a dose-
response eﬀ ect, which was signiﬁ cant for non-colorectal 
Lynch syndrome cancers (p=0·03) and Lynch syndrome 
cancers overall (p=0·007), but not for colorectal cancer 
(p=0·06; table 2). Corresponding outcomes from the 
Poisson regression analysis were also signiﬁ cant (p=0·03 
for non-colorectal Lynch syndrome cancers, p=0·002 for 
Lynch syndrome cancers overall, and p=0·03 for 
colorectal cancer).
The CAPP2 study included a group of participants who 
chose not to be randomly assigned for aspirin and who 
were randomly assigned for the resistant starch 
intervention only. To establish whether the apparent 
protective eﬀ ect of aspirin might be attributable to 
unexpectedly high numbers of cancers in the aspirin 
placebo group, we tested the risk of colorectal cancer for 
the non-randomised group (resistant starch or resistant 
starch placebo only) compared with the aspirin placebo 
group. The HR for colorectal cancer in this group was 
1·4 times higher compared with the aspirin placebo 
group (p=0·4). This ﬁ nding supports the protective eﬀ ect 
of aspirin.
Where possible, details of adenoma development were 
obtained in the postintervention period. Although 
incomplete, these data, gathered by masked contributors, 
revealed no apparent eﬀ ect of aspirin on numbers of 
participants who developed adenomas subsequent to the 
intervention phase—ie, 51 and 48 in the aspirin and 
aspirin placebo groups, respectively.
Hazard ratio Incidence rate ratio†
95% CI* p value 95% CI p value
Colorectal cancer
Intention-to-treat analysis
Aspirin versus aspirin placebo 0·63 (0·35–1·13) 0·12 0·56 (0·32–0·99) 0·05
Per-protocol analysis
≥2 years’ aspirin placebo‡ 1·0 ·· 1·0 ··
<2 years’ aspirin placebo‡ 0·62 (0·25–1·52) 0·30 0·72 (0·32–1·59) 0·41
<2 years’ aspirin‡ 1·07 (0·47–2·41) 0·87 0·90 (0·42–1·91) 0·77
≥2 years’ aspirin‡ 0·41 (0·19–0·86) 0·02 0·37 (0·18–0·78) 0·008
Cumulative aspirin dose
Units of 100 aspirin§ 0·97 (0·94–1·00) 0·06 0·97 (0·94–1·00) 0·03
Non-colorectal Lynch syndrome cancers
Intention-to-treat analysis
Aspirin versus aspirin placebo 0·63 (0·34–1·19) 0·16 0·63 (0·34–1·16) 0·14
Per-protocol analysis
≥2 years’ aspirin placebo‡ 1·0 ·· 1·0 ··
<2 years’ aspirin placebo‡ 0·96 (0·40–2·34) 0·94 0·82 (0·35–1·96) 0·66
<2 years’ aspirin‡ 1·11 (0·46–2·68) 0·82 0·90 (0·38–2·14) 0·81
≥2 years’ aspirin‡ 0·47 (0·21–1·06) 0·07 0·49 (0·23–1·05) 0·07
Cumulative aspirin dose
Units of 100 aspirin§ 0·96 (0·93–1·00) 0·03 0·96 (0·93–1·00) 0·03
All Lynch syndrome cancers
Intention-to-treat analysis
Aspirin versus aspirin placebo 0·65 (0·42–1·00) 0·05 0·59 (0·39–0·90) 0·01
Per-protocol analysis
≥2 years’ aspirin placebo‡ 1·0 ·· 1·0 ··
<2 years’ aspirin placebo‡ 0·79 (0·42–1·49) 0·47 0·76 (0·43–1·37) 0·36
<2 years’ aspirin‡ 1·13 (0·62–2·06) 0·69 0·90 (0·51–1·59) 0·71
≥2 years’ aspirin‡ 0·45 (0·26–0·79) 0·005 0·42 (0·25–0·72) 0·001
Cumulative aspirin dose
Units of 100 aspirin§ 0·97 (0·95–0·99) 0·007 0·96 (0·94–0·99) 0·002
*Cox proportional Hazards analysis based on 48 participants with colorectal cancer (including 53 cancer diagnoses), 
40 cases of non-colorectal Lynch syndrome cancer, and 86 participants with Lynch syndrome cancers (93 cancer 
diagnoses). †Incidence rate ratio from Poisson regression. ‡The threshold for 2 years’ intervention was consumption of 
more than 1400 aspirin tablets; rounded down from a 2-year total of 1461 tablets to allow for early scheduling of the 
exit colonoscopy or occasional missed dosage. §Units of 100 aspirin=total number of aspirin taken divided by 100.
Table 2: Cox proportional hazards analysis and Poisson regression for colorectal cancer, non-colorectal 
Lynch syndrome cancers, and all Lynch syndrome cancers (adjusted for sex) in participants randomly 
assigned to aspirin or aspirin placebo
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The data were analysed according to the underlying 
MMR gene defect; colorectal cancer was reported with 
equal frequency in participants carrying MLH1 and 
MSH2 mutations (6·0% and 7·0%, respectively), and 
none of the MSH6 mutation carriers developed colorectal 
cancer, in keeping with the anticipated milder phenotype 
(webappendix p 7). The remaining 163 recruits were 
diagnosed on the basis of Amsterdam Criteria1 and had 
been treated for a Lynch syndrome-related neoplasia. Of 
these, seven (4%) developed colorectal cancer. Overall, 
there was no evidence of diﬀ erence in incidence of 
colorectal cancer by presence of proven germ-line 
mutation (χ²(2)=3·1, p=0·38).
18 (34%) of 53 colorectal cancers diagnosed in aspirin 
or aspirin placebo groups were Dukes stage A, 21 (40%) 
Dukes B, ten (19%) had Dukes C and D, and four (8%) 
were unknown. 27 (51%) tumours were located in the 
ascending colon, transverse colon, and splenic ﬂ exure, 
six (11%) in the descending colon, 12 (23%) in the sigmoid 
and rectum, and eight (15%) were unknown. There was 
no signiﬁ cant diﬀ erence in staging (χ²(3)=2·92, p=0·40) 
and tumour location (χ²(3)=0·08, p=0·99) between 
aspirin and aspirin placebo groups.
Discussion
The CAPP2 study was the ﬁ rst double-blind randomised 
controlled trial of aspirin chemoprevention with cancer as 
the primary endpoint. The outcome is consistent with 
more than two decades of observational data showing that 
risk of colorectal cancer is halved in regular aspirin 
consumers7 and recent long-term follow-up of aspirin 
trials for cardiovascular disease prevention showing that 
dosing with 75 mg or more of aspirin per day for several 
years reduced deaths from gastrointestinal cancers, 
particularly involving the proximal colon.8,9 This concept 
of delayed cancer chemoprevention was apparent in 
observational studies, in which protection against cancer 
in regular aspirin users took about 10 years to emerge.4,7 
This eﬀ ect was presumed to be dependent on continued 
aspirin exposure, but in the cardiovascular disease trials, 
treatment ended at a mean of 6 years. Analysis of cancer-
related death in eight trials10 revealed signiﬁ cant protection 
in participants allocated aspirin for 4 years or more, but 
only when followed up for a further 5 years. Our ﬁ ndings 
support the hypothesis of a delayed eﬀ ect of aspirin on 
colorectal cancer by showing that aspirin reduced 
incidence of colorectal cancer with the eﬀ ect becoming 
apparent after 3–4 years from the start of aspirin 
intervention, a diﬀ erence consistent with faster cancer 
development in those with Lynch syndrome (panel).11,12
In intention-to-treat analysis, Poisson regression 
analysis, which incorporates more of the follow-up 
information than the time-to-event analysis (ie, total 
number of cancers in follow-up period vs time to ﬁ rst 
cancer), showed similar estimates of the protective eﬀ ect 
but, as anticipated, greater statistical signiﬁ cance. The 
per-protocol analysis showed a similar eﬀ ect.
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Figure 2: Time to ﬁ rst colorectal cancer in participants randomly assigned to aspirin compared with those 
assigned to aspirin placebo
(A) Kaplan-Meier analysis, adjusted for sex. (B) Kaplan-Meier analysis restricted to participants who had taken the 
intervention for 2 years or more, adjusted for sex. Each point on the plots shows the estimated cumulative 
incidence by years of follow-up; error bars show 95% CIs. HR=hazard ratio. CRC=colorectal cancer.
Figure 3: Time to ﬁ rst Lynch syndrome cancer in participants randomly assigned to aspirin compared with 
those assigned to aspirin placebo
Kaplan-Meier analysis restricted to participants who had taken the intervention for 2 years or more, adjusted for 
sex. Each point on the plot shows the estimated cumulative incidence by years of follow-up; error bars show 
95% CIs. HR=hazard ratio.
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In keeping with the eﬀ ect of aspirin on non-colonic 
Lynch syndrome cancers (endometrial cancer, ovarian 
cancer, pancreatic cancer, and cancer of the brain, small 
bowel, gall bladder, ureter, stomach, and kidney) in our 
trial, Rothwell and colleagues10 reported that aspirin 
treatment reduced risk of death from several non-colonic 
solid cancers including oesophageal, pancreatic, brain, 
lung, stomach, and prostate cancer. Whether Lynch 
syndrome cancers are more responsive to aspirin is 
unclear, although in CAPP2 non-Lynch syndrome 
extracolonic cancers seemed unaﬀ ected by aspirin 
intervention. A weakness of our international study was 
the inability to collect a comprehensive series of tumour 
blocks to conﬁ rm that tumour development was related 
to the germline MMR mutation.
Our discovery of substantial protection by aspirin 
against colorectal cancer and other Lynch syndrome 
cancers is in striking contrast with our earlier report3 of 
no eﬀ ect of aspirin on large-bowel neoplasia. Taken 
together, these ﬁ ndings might help to explain the marked 
disparity between the 50% cancer reduction reported in 
observational studies and the outcomes of randomised 
adenoma prevention trials, which have shown at best a 
small reduction eﬀ ect; meta-analysis revealed a pooled 
risk ratio of any adenoma for any dose of aspirin versus 
placebo of 0·83 (95% CI 0·72–0·96).13 Our recent CAPP1 
report2 in carriers of familial adenomatous polyposis 
revealed a small eﬀ ect of aspirin on adenoma progression, 
but no demonstrable eﬀ ect on polyp number, albeit using 
insensitive methods of analysis. In view of the CAPP2 
ﬁ ndings, revisiting the CAPP1 participants to see whether 
aspirin has long-term eﬀ ects on their disease progression 
will be interesting.
Several important questions remain: (1) whether aspirin 
targets the minority of adenomas with the greatest 
malignant potential; (2) whether some Lynch syndrome 
colorectal cancers arise from lesions other than 
adenomas;14 and (3) why do some tumours seem to be 
resistant to the eﬀ ects of aspirin? The mechanism by 
which aspirin suppresses cancer development long after 
cessation of exposure to the drug is unclear. The assumed 
primary action of anti-inﬂ ammatory drugs on COX2 in 
colonic tumours15 is unlikely to be the primary mech-
anism. The rapid progression from adenoma to carcinoma 
in Lynch syndrome12 makes it likely that many screen-
detected cancers would have begun to develop after 
aspirin intervention ended. Aspirin might be proapoptotic 
at early stages of colorectal cancer development, perhaps 
preceding adenoma formation. Ruschoﬀ  and colleagues16,17 
reported reduced micro satellite instability and increased 
apoptosis in MMR-deﬁ cient cells exposed to aspirin and 
argued that aspirin might induce genetic selection for 
microsatellite stability in a subset of MMR-deﬁ cient cells. 
Aspirin might delete those aberrant stem cells most likely 
to progress rapidly to cancer. Analysis of the conditional 
MSH2 knockout mouse, reported recently to survive 
signiﬁ cantly longer when exposed to aspirin,18 might shed 
light on the mechanism.
Despite regular colonoscopy, almost one in 14 partici-
pants not taking aspirin in CAPP2 developed colorectal 
cancer in less than 5 years, emphasising the need for 
additional prevention strategies. Our results, taken in 
conjunction with recent research, provide a basis for 
recommendation of aspirin chemoprevention in Lynch 
syndrome as standard of care. CAPP3 will seek to establish 
the optimum dose and duration of aspirin treatment.
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Systematic review
We have accessed, using PubMed and our professional networks, all publications related 
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follow-up registry data derived from participants in randomised controlled trials of aspirin 
as a means of preventing occlusive vascular disease.10 Randomised trials based on 
prevention of colorectal adenomas as a biomarker of cancer showed an equivocal eﬀ ect, 
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Interpretation
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appropriate measures to minimise adverse eﬀ ects. Indirect evidence suggests that a lower 
dose of aspirin than was used here will have a protective eﬀ ect and its use would not 
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